My name is Pavas Mehra we are here at
Pareto Securities' annual healthcare
conference in Stockholm and with me I
have Anders Rabbe CEO of Isofol Medical
welcome and thank you for having me here
could you please tell us a little bit
more about this of all and yeah the
product that you are developing yes so
we are developing a drug called Arfolitixorin or in its intended for treating
colorectal cancer and it's we can you
know hopefully improve the therapy by
increasing the efficacy of the the key
therapy for colorectal cancer which is
cytotoxic agents which reduces cancer
cell growth and we with Arfolitixorin
we provide a substance called MTHF which increase the efficacy of these
cytotoxic and we not just now we have a
phase 3 trial ongoing in Europe US and
Canada we have more than 70 hospitals
including patients and we intend to have
some readouts from this trial during
2020 where we're doing interim analysis
at the same time we have of course a lot
of discussions and around the world with
potential partners we are increasing
your awareness regarding our potential
to improve the therapy for these
patients with colorectal cancer and
particularly we are treating metastatic
colorectal cancer and we are targeting
patients in the first line meaning
initial treatment and basically this is
the first potential new drug for this
patient in the last 15 years that means
that we have a big interest from from
key opinion leaders and physicians and
and also patients to participate in this
trial and you have quite a large
addressable market I assume there are
365,000 incidents of colorectal
cancer in US Europe and Japan
well actually the incidence is much
larger but the illegible patients who
could get treated with cytotoxic agents
are those who unfortunately have a more
severe disease and that's around these
360,000 patients this is not including
China or the rest of the world
and we think by targeting these patients
in the first line and based on the
primary market research we have done
throughout the years more than sixty to
seventy thousand patients with nine
months treatment indicates with the
pricing indications that we have that
this is a billion-dollar opportunity for
for commercialization in going forward
and you mentioned that there will be
some phase three readouts are there any
other events like out of an investor
perspective that we can be on the
lookout for well we have other trials
ongoing so basically in during the next
spring we will have data from the Phase
two trial which is ongoing in the same
parallel and the reason for this is that
we want to have data to present that
different medical congress's like ask a
meeting in Chicago and so forth so this
you can have a look at for we also have
informed the market that we have an
intention to to move our listing from
First North Premiere to Nasdaq Main Market so these are some potential
events that can increase the interest
for for our company and also the
interest for potential investors to buy
shares that sounds interesting thank you
for being here today and we're looking
forward to following you head
thanks so much for having me
